Ciliary neurotrophic factor

Last updated
CNTF
Protein CNTF PDB 1cnt.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases CNTF , Hciliary neurotrophic factor
External IDs OMIM: 118945; MGI: 88439; HomoloGene: 8288; GeneCards: CNTF; OMA:CNTF - orthologs
Orthologs
SpeciesHumanMouse
Entrez

1270

12803

Ensembl

ENSG00000242689

ENSMUSG00000079415

UniProt

P26441

P51642

RefSeq (mRNA)

NM_000614

NM_053007
NM_170786

RefSeq (protein)

NP_000605

NP_740756

Location (UCSC) Chr 11: 58.62 – 58.63 Mb Chr 19: 12.74 – 12.74 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Ciliary neurotrophic factor is a protein that in humans is encoded by the CNTF gene. [5] [6] [7]

Contents

The protein encoded by this gene is a polypeptide hormone and neurotrophic factor whose actions have mainly been studied in the nervous system where it promotes neurotransmitter synthesis and neurite outgrowth in certain neural populations including astrocytes. It is a hypothalamic neuropeptide that is a potent survival factor for neurons and oligodendrocytes and may be relevant in reducing tissue destruction during inflammatory attacks. A mutation in this gene, which results in aberrant splicing, leads to ciliary neurotrophic factor deficiency, but this phenotype is not causally related to neurologic disease. In addition to the predominant monocistronic transcript originating from this locus, the gene is also cotranscribed with the upstream ZFP91 gene. Cotranscription from the two loci results in a transcript that contains a complete coding region for the zinc finger protein but lacks a complete coding region for ciliary neurotrophic factor. [7]

CNTF has also been shown to be expressed by cells on the bone surface, and to reduce the activity of bone-forming cells (osteoblasts). [8]

Therapeutic applications

Satiety effects

In 2001, it was reported that in a human study examining the usefulness of CNTF for treatment of motor neuron disease, CNTF produced an unexpected and substantial weight loss in the study subjects. Further investigation revealed that CNTF could reduce food intake without causing hunger or stress, making it a candidate for weight control in leptin-resistant subjects, as CNTF is believed to operate like leptin, but by a non-leptin pathway. [9]

Recombinant human CNTF (Axokine)

A recombinant version of human CNTF (rhCNTF), trade name Axokine, is a modified version with a 15 amino acid truncation of the C-terminus and two amino acid substitutions. It is three to five times more potent than CNTF in in vitro and in vivo assays and has improved stability properties. [10] Like CNTF it is a neurotrophic factor, and may stimulate nerve cells to survive. It was tested in the 1990s as a treatment for amyotrophic lateral sclerosis. It did not improve muscle control as much as expected, but trial participants did report a loss of appetite.

Phase III clinical trials for the drug against obesity were conducted in 2003 by Axokine's maker, Regeneron Pharmaceuticals, demonstrating a small positive effect in some patients, but the drug was not commercialized. A major problem with the treatment was that in nearly 70% of the subjects tested, antibodies against Axokine were produced after approximately three months of treatment. [11] In the minority of subjects who did not develop the antibodies, weight loss averaged 12.5 pounds in one year, versus 4.5 pounds for placebo-treated subjects. In order to obtain this benefit, subjects needed to receive daily subcutaneous injections of one microgram Axokine per kilogram body weight.

Xencor patent application raises the disturbing idea that subjects producing antibodies against CNTF analogues may eventually suffer severe adverse effects, as these antibodies could potentially interfere with the neuroprotective functions of endogenous CNTF. [12] The application claims methods of designing CNTF analogues with lower immunogenicity than Axokine based on analysis of affinity of each modified epitope for each of 52 class II MHC alleles, and provides specific examples of such modifications. No such analogues are currently listed in Xencor's product pipeline. [13]

NT-501

NT-501 is a product being developed by Neurotech that consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). In a clinical trial, NT-501 demonstrated a statistically significant reduction of photoreceptor degradation in patients with retinitis pigmentosa. [14] [15]

Interactions

Human ciliary neurotrophic factor has been shown to interact with the Interleukin 6 receptor. [16] [17]

See also

Related Research Articles

<span class="mw-page-title-main">Brain-derived neurotrophic factor</span> Protein found in humans

Brain-derived neurotrophic factor (BDNF), or abrineurin, is a protein that, in humans, is encoded by the BDNF gene. BDNF is a member of the neurotrophin family of growth factors, which are related to the canonical nerve growth factor (NGF), a family which also includes NT-3 and NT-4/NT-5. Neurotrophic factors are found in the brain and the periphery. BDNF was first isolated from a pig brain in 1982 by Yves-Alain Barde and Hans Thoenen.

<span class="mw-page-title-main">Agouti-related peptide</span> Mammalian protein found in Homo sapiens

Agouti-related protein (AgRP), also called agouti-related peptide, is a neuropeptide produced in the brain by the AgRP/NPY neuron. It is synthesized in neuropeptide Y (NPY)-containing cell bodies located in the ventromedial part of the arcuate nucleus in the hypothalamus. AgRP is co-expressed with NPY and acts to increase appetite and decrease metabolism and energy expenditure. It is one of the most potent and long-lasting of appetite stimulators. In humans, the agouti-related peptide is encoded by the AGRP gene.

<span class="mw-page-title-main">Glial cell line-derived neurotrophic factor</span> Protein-coding gene in the species Homo sapiens

Glial cell line-derived neurotrophic factor (GDNF) is a protein that, in humans, is encoded by the GDNF gene. GDNF is a small protein that potently promotes the survival of many types of neurons. It signals through GFRα receptors, particularly GFRα1. It is also responsible for the determination of spermatogonia into primary spermatocytes, i.e. it is received by RET proto-oncogene (RET) and by forming gradient with SCF it divides the spermatogonia into two cells. As the result there is retention of spermatogonia and formation of spermatocyte.

<span class="mw-page-title-main">George Yancopoulos</span> American biomedical scientist (born 1959)

George D. Yancopoulos is a Greek-American biomedical scientist who is the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals.

<span class="mw-page-title-main">Tropomyosin receptor kinase B</span> Protein and coding gene in humans

Tropomyosin receptor kinase B (TrkB), also known as tyrosine receptor kinase B, or BDNF/NT-3 growth factors receptor or neurotrophic tyrosine kinase, receptor, type 2 is a protein that in humans is encoded by the NTRK2 gene. TrkB is a receptor for brain-derived neurotrophic factor (BDNF). The standard pronunciation for this protein is "track bee".

<span class="mw-page-title-main">Tropomyosin receptor kinase C</span> Protein-coding gene in the species Homo sapiens

Tropomyosin receptor kinase C (TrkC), also known as NT-3 growth factor receptor, neurotrophic tyrosine kinase receptor type 3, or TrkC tyrosine kinase is a protein that in humans is encoded by the NTRK3 gene.

Neurotrophic factors (NTFs) are a family of biomolecules – nearly all of which are peptides or small proteins – that support the growth, survival, and differentiation of both developing and mature neurons. Most NTFs exert their trophic effects on neurons by signaling through tyrosine kinases, usually a receptor tyrosine kinase. In the mature nervous system, they promote neuronal survival, induce synaptic plasticity, and modulate the formation of long-term memories. Neurotrophic factors also promote the initial growth and development of neurons in the central nervous system and peripheral nervous system, and they are capable of regrowing damaged neurons in test tubes and animal models. Some neurotrophic factors are also released by the target tissue in order to guide the growth of developing axons. Most neurotrophic factors belong to one of three families: (1) neurotrophins, (2) glial cell-line derived neurotrophic factor family ligands (GFLs), and (3) neuropoietic cytokines. Each family has its own distinct cell signaling mechanisms, although the cellular responses elicited often do overlap.

<span class="mw-page-title-main">Neurotrophin-3</span> Protein-coding gene in the species Homo sapiens

Neurotrophin-3 is a protein that in humans is encoded by the NTF3 gene.

<span class="mw-page-title-main">Interleukin 31</span>

Interleukin-31 (IL-31) is a protein that in humans is encoded by the IL31 gene that resides on chromosome 12. IL-31 is an inflammatory cytokine that helps trigger cell-mediated immunity against pathogens. It has also been identified as a major player in a number of chronic inflammatory diseases, including atopic dermatitis.

<span class="mw-page-title-main">Neurotrophin-4</span> Protein-coding gene in the species Homo sapiens

Neurotrophin-4 (NT-4), also known as neurotrophin-5 (NT-5), is a protein that in humans is encoded by the NTF4 gene. It is a neurotrophic factor that signals predominantly through the TrkB receptor tyrosine kinase. NT-4 was first discovered and isolated from xenopus and viper in the year 1991 by Finn Hallbook et.al

<span class="mw-page-title-main">Artemin</span> Protein-coding gene in the species Homo sapiens

Artemin, also known as enovin or neublastin, is a protein that in humans is encoded by the ARTN gene.

<span class="mw-page-title-main">Glial scar</span> Mass formed in response to injury to the nervous system

A glial scar formation (gliosis) is a reactive cellular process involving astrogliosis that occurs after injury to the central nervous system. As with scarring in other organs and tissues, the glial scar is the body's mechanism to protect and begin the healing process in the nervous system.

<span class="mw-page-title-main">Interleukin-6 receptor</span> Protein-coding gene in the species Homo sapiens

Interleukin 6 receptor (IL6R) also known as CD126 is a type I cytokine receptor.

<span class="mw-page-title-main">Metabotropic glutamate receptor 6</span> Mammalian protein found in humans

Glutamate receptor, metabotropic 6, also known as GRM6 or mGluR6, is a protein which in humans is encoded by the GRM6 gene.

<span class="mw-page-title-main">Interleukin 10 receptor, beta subunit</span> Protein-coding gene in the species Homo sapiens

Interleukin 10 receptor, beta subunit is a subunit for the interleukin-10 receptor. IL10RB is its human gene.

<span class="mw-page-title-main">GRIN3B</span> Protein-coding gene in the species Homo sapiens

Glutamate [NMDA] receptor subunit 3B is a protein that in humans is encoded by the GRIN3B gene.

<span class="mw-page-title-main">CLCF1</span> Protein-coding gene in the species Homo sapiens

Cardiotrophin-like cytokine factor 1 (CLCF1), also known as Novel Neurotrophin-1 (NNT-1) or B cell-stimulating factor-3 (BSF-3), is a protein that in humans is encoded by the CLCF1 gene.

<span class="mw-page-title-main">GLRB</span> Protein-coding gene in the species Homo sapiens

Glycine receptor subunit beta is a protein that in humans is encoded by the GLRB gene.

<span class="mw-page-title-main">CRLF1</span> Protein-coding gene in the species Homo sapiens

Cytokine receptor-like factor 1 is a protein that in humans is encoded by the CRLF1 gene.

Zinc finger protein 91 homolog (mouse), ciliary neurotrophic factor transcription unit, also known as ZFP91-CNTF, is a human gene.

References

  1. 1 2 3 GRCh38: Ensembl release 89: ENSG00000242689 – Ensembl, May 2017
  2. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000079415 – Ensembl, May 2017
  3. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ Lam A, Fuller F, Miller J, Kloss J, Manthorpe M, Varon S, Cordell B (Sep 1991). "Sequence and structural organization of the human gene encoding ciliary neurotrophic factor". Gene. 102 (2): 271–6. doi:10.1016/0378-1119(91)90089-T. PMID   1840538.
  6. ↑ Bazan JF (Sep 1991). "Neuropoietic cytokines in the hematopoietic fold". Neuron. 7 (2): 197–208. doi:10.1016/0896-6273(91)90258-2. PMID   1714745. S2CID   24161982.
  7. 1 2 "Entrez Gene: CNTF ciliary neurotrophic factor".
  8. ↑ McGregor NE, Poulton IJ, Walker EC, Pompolo S, Quinn JM, Martin TJ, Sims NA (Mar 2010). "Ciliary neurotrophic factor inhibits bone formation and plays a sex-specific role in bone growth and remodeling". Calcified Tissue International. 86 (3): 261–70. doi:10.1007/s00223-010-9337-4. PMID   20157807. S2CID   23699865.
  9. ↑ Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ (2001). "Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity". Proc. Natl. Acad. Sci. U.S.A. 98 (8): 4652–7. doi: 10.1073/pnas.061034298 . PMC   31889 . PMID   11259650.
  10. ↑ Peterson WM, Wang Q, Tzekova R, Wiegand SJ (June 2000). "Ciliary neurotrophic factor and stress stimuli activate the Jak-STAT pathway in retinal neurons and glia". J. Neurosci. 20 (11): 4081–90. doi:10.1523/JNEUROSCI.20-11-04081.2000. PMC   6772642 . PMID   10818143.
  11. ↑ "Axokine from Regeneron (REGN): Unexpected Antibodies and Modest Efficacy in Phase III Study". Press Release. Regeneron Pharmaceuticals. 2003-03-31. Retrieved 2011-08-20.
  12. ↑ USapplication 2005064555,Marshall S, Barbosa M,"Ciliary neurotrophic factor variants",published 2005-03-24
  13. ↑ "Product Pipeline". Xencor. Retrieved 2011-08-20.
  14. ↑ Talcott KE, Ratnam K, Sundquist SM, Lucero AS, Lujan BJ, Tao W, Porco TC, Roorda A, Duncan JL (April 2011). "Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment". Invest. Ophthalmol. Vis. Sci. 52 (5): 2219–26. doi:10.1167/iovs.10-6479. PMC   3080173 . PMID   21087953.
  15. ↑ "Neurotech's NT-501 Implant Demonstrates Statistically Significant Photoreceptor Preservation in Patients with Retinal Degenerative Disease". Business Wire. 2011-04-11. Retrieved 2011-08-20.
  16. ↑ Schuster B, Kovaleva M, Sun Y, Regenhard P, Matthews V, Grötzinger J, Rose-John S, Kallen KJ (March 2003). "Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF". J. Biol. Chem. 278 (11): 9528–35. doi: 10.1074/jbc.M210044200 . PMID   12643274.
  17. ↑ Schooltink H, Stoyan T, Roeb E, Heinrich PC, Rose-John S (December 1992). "Ciliary neurotrophic factor induces acute-phase protein expression in hepatocytes". FEBS Lett. 314 (3): 280–4. Bibcode:1992FEBSL.314..280S. doi: 10.1016/0014-5793(92)81489-9 . PMID   1281789. S2CID   39538295.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.